GlassScriptPhysician profile
Amit Patel
NPI 1396409884
$4,441.43
in general payments reported to CMS, 2019-2025
25 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $624 · 2023: $1,496 · 2024: $938 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,737 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.47 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.49 | 2022-2025 | |
| Dermavant Sciences, INC. | $461.32 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $387.44 | 2022-2024 | Winlevi, Ilumya, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $318.80 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $294.87 | 2023-2025 | Dupixent |
| Galderma Laboratories, L.P. | $200.48 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $178.02 | 2023-2024 | |
| Genzyme Corporation | $173.59 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $170.62 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $169.04 | 2023 | |
| Incyte Corporation | $126.41 | 2024-2025 | Opzelura |
| Amgen INC. | $94.12 | 2023-2024 | Otezla |
| Lilly USA, LLC | $89.04 | 2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $85.89 | 2025 | Anzupgo, Adbry |
| Organon LLC | $82.54 | 2025 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $65.34 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Janssen Biotech, INC. | $43.61 | 2024-2025 | Tremfya |
| Vertex Pharmaceuticals Incorporated | $32.94 | 2025 | |
| Cipher Pharmaceuticals US LLC | $31.76 | 2025 | Spinosad, Natroba |
| Angiodynamics, INC. | $30.92 | 2025 | Alphavac |
| Organogenesis INC. | $26.03 | 2024 | |
| Botanix Sb INC | $23.05 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $17.41 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $14.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.